+ 12,3 % bei Geron (902213) Was ist los? o. T.

Gestern nach Börsenschluss mit -25% und heute deutlich im Plus....Was für eine Kurs-Verwerfung ,sieht man auch nicht jeden Tag

muss mal jemand verstehen, aber gut, mir soll es recht sein.

75 Mio. $ Offering

• 53,3 Mio. Aktien + warrants zu 1,05$
  

ir.geron.com/investors/press-releases/...arrants/default.aspx

Rational nachvollziehbar ist dieser Kursananstieg (nach Bekanntgabe dieses Offerings) jedenfalls nicht.

GERN's drug imetelstat called the Future Oncology. "Published by John Mascarenhas, MD and team on May 2, 2022.
Dr. Mascarenhas received research grant/funding from Incyte, Novartis, CTI BioPharma, Geron, PharmaEssentia, AbbVie, Bristol Myers Squibb, Celgene, Roche, Kartos, Promedior, and Merck in addition to many others. (Pay attention to big pharmas who are sponsoring the study)
The study designed to compare Imetelstat against two BAT; JAK inhibitors, ruxolitinib and fedratinib. An excellent study with no risk to patients.
Imetelstat vs. BAT, follow up visit after treatment ended. If progressive disease with BAT, patients were eligible for crossover to Imetelstat."
“They concluded that the study has the potential to change the treatment landscape in refractory MF and address a critical unmet need for disease-modifying therapies that will improve survival in this poor-prognosis patient population.”
(BAT is best available current treatments)

"Aus wettbewerblicher Sicht ist es ein Hindernis und ein Nachteil für $GERN und seine Entwicklung von imetelstat."

twitter.com/adamfeuerstein/status/...cxt=HHwWgMC4wZ3mpoYsAAAA

Heute werden die Phase3 Daten der IMerge Studie diskutiert. Bei negativen Daten halte ich einen Kursrückgang von über 70% für möglich. Sollte die Daten positiv ausfallen, bin ich gespannt, ob und wie weit der Kurs dann anspringen würde. Um 14 Uhr startet der CC.
ir.geron.com/investors/press-releases/...Phase-3/default.aspx

positive Studienergebnisse

ir.geron.com/investors/press-releases/...isk-MDS/default.aspx

Geron Corporation Announces Proposed Public Offering of Common Stock

...today announced that it intends to offer and sell $175 million of shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Geron. Geron intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

finance.yahoo.com/news/...nces-proposed-public-211900778.html

Das 175 Mio. $ Offering würgt den Kursanstieg natürlich ziemlich ab. Mal sehen zu welchem Preis je Aktie das Offering stattfinden soll.
ir.geron.com/investors/press-releases/...n-Stock/default.aspx

Die Anküdigung des Offerings bringt den Kurs unter Druck.

Pricing

• 55,8 Mio. neue Aktien zu je 2,45$
• 25 Mio. warrants zu je 2,449$
  
• Volumen insgesamt 198 Mio. $
  

ir.geron.com/investors/press-releases/...arrants/default.aspx

Überlege nachzukaufen...da scheint irgendwas zu kommen

Primary endpoint of 8-week transfusion independence (TI) significantly higher with imetelstat vs. placebo (P<0.001), with median TI duration approaching one year for imetelstat 8-week TI responders

Statistically significant and clinically meaningful efficacy results achieved across key MDS subgroups: ring sideroblast (RS) status, baseline transfusion burden and IPSS risk category

Safety results consistent with prior imetelstat clinical experience

Reduction in variant allele frequency (VAF) of genes commonly mutated in MDS and their correlation with clinical endpoints support disease-modifying potential of imetelstat

Data support NDA submission which is on track for June 2023 to support potential U.S. commercial launch in first half of 2024

finance.yahoo.com/news/...esentation-reporting-193000539.html

150 Mio. $ Offering

• 42 Mio. neue Aktien zu je 3$
  

ir.geron.com/investors/press-releases/...arrants/default.aspx

FDA Zulassung für RYTELO

https://pharmaphorum.com/news/...brings-drug-market-fda-clears-rytelo

Nein, kaufe nicht bei diesen Kursen

https://de.investing.com/news/stock-market-news/...e-ein-93CH-2892779

aufwärts , Geron scheint wohl 2026 die Kurve zu kriegen, da nun die Gewinnzone in Sichtweite ist.  

steigt wieder, seit einem Quartal ist der Kurs stark angestiegen.  

gibt es die Zahlen.